<DOC>
	<DOCNO>NCT02937844</DOCNO>
	<brief_summary>CAR T cell immunotherapy achieve great success CD19+ B-cell malignancy . Whether new generation cell-based immunotherapy apply solid tumor remain investigated , partly due hostile immune-suppressive tumor microenvironment favor tumor growth immune system . Signaling pathway program death 1 ( PD-1 ) ligand PD-L1 play important role suppress immune response tumor . PD-L1 over-expressed 88 % glioblastoma . We construct chimeric switch receptor ( CSR ) contain extracellular domain PD1 fuse transmembrane cytoplasmic domain costimulatory molecule CD28 . CSR modify T cell able recognize PD-L1-expressing tumor cell transduce signal activate T cell , result tumor kill . A truncated EGFR ( tEGFR ) lack ligand bind domain cytoplasmic kinase domain wildtype EGFR incorporate CSR vector use vivo track ablation CSR T cell necessary . This pilot study determine safety efficacy autologous CSR T cell patient recurrent glioblastoma .</brief_summary>
	<brief_title>Pilot Study Autologous Chimeric Switch Receptor Modified T Cells Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1. ability understand willingness provide write informed consent ; 2. patient ≥ 18 ≤ 70 year old ; 3. recurrent glioblastoma patient measurable tumor . Patients receive standard care medication , Gross Total Resection concurrent Radiochemotherapy ( ~54 60 Gy , TMZ ) . Patients must either receive dexamethasone receive ≤ 4 mg/day time leukopheresis ; 4 . Malignant cell PDL1 positive confirm IHC ; 5. karnofsky performance score ( KPS ) ≥ 60 ; 6. life expectancy &gt; 3 month ; 7. satisfactory bone marrow , liver kidney function define follow : absolute neutrophile count ≥ 1500/mm^3 ; hemoglobin &gt; 10 g/dL ; platelet &gt; 100000 /mm^3 ; Bilirubin &lt; 1.5×ULN ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5×ULN ; creatinine &lt; 1.5×ULN ; 8. peripheral blood absolute lymphocyte count must 0.8×10^9/L ; 9. satisfactory heart function ; 10. patient must willing follow order doctor ; 11. woman reproductive potential ( 15 49 year old ) must negative pregnancy test within 7 day study start . Male female patient reproductive potential must agree use birth control study 3 month post study . 1. prior history gliadel implantation 4 week study start antibody base therapy ; 2 . HIV positive ; 3. hepatitis B infection hepatitis C infection ; 4. history autoimmune disease , diseases require longterm administration steroid immunosuppressive therapy ; 5. history allergic disease , allergy CAR T cell study product excipients ; 6. patient already enrol clinical study ; 7. patient , opinion investigator , may eligible able comply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>